These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19393583)

  • 1. Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
    Celis JE; Cabezón T; Moreira JM; Gromov P; Gromova I; Timmermans-Wielenga V; Iwase T; Akiyama F; Honma N; Rank F
    Mol Oncol; 2009 Jun; 3(3):220-37. PubMed ID: 19393583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
    Celis JE; Gromov P; Cabezón T; Moreira JM; Friis E; Jirström K; Llombart-Bosch A; Timmermans-Wielenga V; Rank F; Gromova I
    Mol Cell Proteomics; 2008 Oct; 7(10):1795-809. PubMed ID: 18632593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.
    Gromov P; Espinoza JA; Talman ML; Honma N; Kroman N; Timmermans Wielenga V; Moreira JM; Gromova I
    PLoS One; 2014; 9(11):e112024. PubMed ID: 25389781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
    Celis JE; Gromova I; Gromov P; Moreira JM; Cabezón T; Friis E; Rank F
    FEBS Lett; 2006 May; 580(12):2935-44. PubMed ID: 16631754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
    Celis JE; Moreira JM; Gromova I; Cabezón T; Gromov P; Shen T; Timmermans V; Rank F
    Mol Oncol; 2007 Jun; 1(1):97-119. PubMed ID: 19383289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
    Celis JE; Gromov P; Moreira JM; Cabezón T; Friis E; Vejborg IM; Proess G; Rank F; Gromova I
    Mol Cell Proteomics; 2006 Mar; 5(3):462-83. PubMed ID: 16316978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
    Tramm T; Kim JY; Tavassoli FA
    Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation.
    Nakamura H; Kukita Y; Kunimasa K; Kittaka N; Kusama H; Nakayama T; Tamaki Y; Sugiura R; Yasuda H; Hashimoto M; Yamamoto T; Imamura F; Nakatsuka SI
    Hum Pathol; 2021 Oct; 116():39-48. PubMed ID: 34314764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
    Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
    Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
    D'Arcy C; Quinn CM
    J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions.
    Chantzi NI; Palaiologou M; Stylianidou A; Goutas N; Vassilaros S; Kourea HP; Dhimolea E; Mitsiou DJ; Tiniakos DG; Alexis MN
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):1057-66. PubMed ID: 24671226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast.
    Vranic S; Gurjeva O; Frkovic-Grazio S; Palazzo J; Tawfik O; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2011 Oct; 19(5):413-6. PubMed ID: 21436679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of androgen receptor and forkhead-box A1 protein in apocrine breast carcinoma.
    Sasahara M; Matsui A; Ichimura Y; Hirakata Y; Murata Y; Marui E
    Anticancer Res; 2014 Mar; 34(3):1261-7. PubMed ID: 24596370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast.
    D'Arcy C; Quinn C
    J Clin Pathol; 2019 Jan; 72(1):1-6. PubMed ID: 30409840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-operative breast pathology: apocrine lesions.
    Wells CA; El-Ayat GA
    J Clin Pathol; 2007 Dec; 60(12):1313-20. PubMed ID: 18042688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.